Millendo Therapeutics, Inc. (MLND) |
| 1.06 -0.06 (-5.36%) 06-28 00:00 |
| Open: | 1.12 |
| High: | 1.13 |
| Low: | 1.06 |
| Volume: | 1,912,625 |
| Market Cap: | 11(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.55 |
| Resistance 1: | 1.36 |
| Pivot price: | 1.35 |
| Support 1: | 1.06 |
| Support 2: | 0.88 |
| 52w High: | 41.549793 |
| 52w Low: | 1.06 |
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Financials
| EPS | -1.930 |
| Book Value | 1.740 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -38.0 |
| Return on Equity (ttm) | -77.8 |
Company news
Tue, 30 Mar 2021
Millendo To Merge With Tempest Therapeutics; Shares Tank - TipRanks
Mon, 29 Mar 2021
Millendo To Merge With Tempest Therapeutics In An All-Stock Transaction - Nasdaq
Tue, 09 Jun 2020
Dwindling Prader-Willi Syndrome Drug Development Landscape And Hopeful Therapies - RTTNews
Tue, 07 Apr 2020
Millendo Therapeutics tanks as it stops livoletide development in PWS - The Pharma Letter
Fri, 07 Dec 2018
Waltham biotech OvaScience shuts down as reverse merger closes - The Business Journals
Fri, 10 Aug 2018
Merger to create leading rare endocrine disease company - The Pharma Letter
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
